G. Collins

发表

Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.

D. Niewoehner, J. Connett, J. Vestbo, 2016, The Lancet. Respiratory medicine.

Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons.

N. Crum‐Cianflone, M. Bavaro, G. Collins, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Relationship between carotenoids and cancer. The multiple risk factor intervention trial (MRFIT) study

L. Kuller, J. Connett, B. Polk, 1989, Cancer.

Randomized, controlled trial of caloric supplements in HIV infection

C. Gibert, D. Wheeler, G. Collins, 1999 .

Protein intake is positively associated with body cell mass in weight-stable HIV-infected men.

D. Wheeler, G. Collins, G. Bartsch, 2003, The Journal of nutrition.

Randomized, controlled trial of caloric supplements in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS.

C. Gibert, D. Wheeler, G. Collins, 1999, Journal of acquired immune deficiency syndromes.

Long-Term Effects of Chlorthalidone Versus Hydrochlorothiazide on Electrocardiographic Left Ventricular Hypertrophy in the Multiple Risk Factor Intervention Trial

E. Soliman, R. Prineas, J. Neaton, 2011, Hypertension.

Lung Function Decline in Early HIV Infection: Impact of Antiretroviral Drug Timing and Drug Regimen.

J. Connett, J. Baker, K. Kunisaki, 2019, American journal of respiratory and critical care medicine.

Association of Methicillin-Resistant Staphylococcus aureus (MRSA) Colonization With High-Risk Sexual Behaviors in Persons Infected With Human Immunodeficiency Virus (HIV)

B. Agan, A. Weintrob, N. Crum‐Cianflone, 2011, Medicine.

Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease

R. Davey, A. Phillips, J. Lundgren, 2014, AIDS.

Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial

T. Aufderheide, J. Tolar, M. Biros, 2020, The Lancet.

Clinical and Population Studies Long-Term Effects of Chlorthalidone Versus Hydrochlorothiazide on Electrocardiographic Left Ventricular Hypertrophy in the Multiple Risk Factor Intervention Trial

E. Soliman, R. Prineas, J. Neaton, 2011 .

Nutrient Requirements — Research Communication Protein Intake Is Positively Associated with Body Cell Mass in Weight-Stable HIV-Infected Men 1

D. Wheeler, G. Collins, G. Bartsch, 2003 .

Immunoglobulin G subclass levels and antibody responses to the 2009 influenza A (H1N1) monovalent vaccine among human immunodeficiency virus (HIV)‐infected and HIV‐uninfected adults

B. Agan, N. Crum‐Cianflone, J. Maguire, 2012, Clinical and experimental immunology.

Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study

D. Snydman, J. Lundgren, J. Neaton, 2021, Transplant infectious disease : an official journal of the Transplantation Society.

Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

A. Winston, R. Price, B. Brew, 2015, HIV medicine.

Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease.

A. Devoe, G. Collins, D. Cowen, 1974, The New England journal of medicine.

Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019

M. Moradi-Lakeh, S. Safiri, J. Kaufman, 2022, Frontiers in Endocrinology.

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.

C. Pettinelli, J. Hodges, M. Loveless, 1996, The New England journal of medicine.

Interleukin-2 therapy in patients with HIV infection.

H. Lane, D. Cooper, A. Phillips, 2009, The New England journal of medicine.

Nonalcoholic Fatty Liver Disease Among HIV-Infected Persons

N. Crum‐Cianflone, A. Lifson, M. Bavaro, 2009, Journal of acquired immune deficiency syndromes.

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis

S. Hammer, D. Katzenstein, R. Schooley, 2000 .

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

Gary Collins, J. Lawrence, K. H. Hullsiek, 2003, The New England journal of medicine.

Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial.

J. Cutler, R. Prineas, S. MacMahon, 1989, The American journal of cardiology.

No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts

A. Winston, J. Lundgren, R. Price, 2018, AIDS (London).

Associations between baseline biomarkers and lung function in HIV-positive individuals

R. Wood, J. Baker, C. Wendt, 2019, AIDS.

Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy

A. Melzer, K. Crothers, M. Ristola, 2018, Journal of acquired immune deficiency syndromes.

Pulmonary function in an international sample of HIV‐positive, treatment‐naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

D. Niewoehner, C. Kityo, E. Tedaldi, 2015, HIV medicine.

Losartan to reduce infl ammation and fibrosis endpoints in HIV disease

J. Neaton, T. Schacker, R. Tracy, 2021 .

Losartan to reduce inflammation and fibrosis endpoints in HIV disease (LIFE-HIV): results from a randomized placebo-controlled trial.

J. Neaton, T. Schacker, R. Tracy, 2020, AIDS.

Body Weight Change, All-Cause Mortality, and Cause-specific Mortality in the Multiple Risk Factor Intervention Trial

K. Brownell, S. Blair, L. Lissner, 1993, Annals of Internal Medicine.

Reply to "nonalcoholic fatty liver disease among HIV-infected persons"

N. Crum‐Cianflone, A. Lifson, M. Bavaro, 2010 .

P63 Design of a randomized trial of combined nucleoside analog antiretroviral therapy in AIDS patients

T. Church, L. Saravolatz, D. Winslow, 1993 .

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

T. Harrer, A. Winston, E. Harrer, 2023, Scientific Reports.

Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons.

N. Crum‐Cianflone, M. Bavaro, G. Collins, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.